Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 17Burkitt Lymphoma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Rectal Neoplasms 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lung Neoplasms 2Leukemia, Biphenotypic, Acute 2Immunoglobulin Light-chain Amyloidosis 2Down Syndrome 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1Rhabdoid Tumor 1Recurrence 1Prolactinoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmacytoma 1Pituitary Neoplasms 1Oropharyngeal Neoplasms 1Optic Nerve Glioma 1Oligodendroglioma 1Neoplasms, Plasma Cell 1Mesothelioma 1Medulloblastoma 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1

Interventions

navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1dexamethasone acetate 1dexamethasone 21-phosphate 1carfilzomib 1auricularum 1Specimen Handling 1Lenalidomide 1Dexamethasone 1Calcium Dobesilate 1Biopsy 12-(5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-(1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Plasmacytoma × Calcium Dobesilate × Clear all
NCT03031730 2026-02-10

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Terminated
35 enrolled 10 charts
Plasma cell

Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡